Skip to content

Clinical study, to Investigate the Safety and Device Performance of Pars Plana Vitrectomy Surgery Using a Hypersonic Vitrector Handpiece.

A Study to Investigate the Safety and Device Performance of Pars Plana Vitrectomy Surgery Using a Hypersonic Vitrector Handpiece

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/07/008975
Enrollment
20
Registered
2017-07-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- For vitrectomy based on a diagnosis of one of the following conditions: vitreoretinal traction, asteroid hyalosis, macular pucker/epiretinal membrane, macular hole, or vitreous hemorrhage

Interventions

Intervention1: Hypersonic vitrector is an ultrasonic handpiece attached to the Stellaris Elite Vision Enhancement System: The hypersonic vitrector is an ultrasonic handpiece that is attached to the S

Sponsors

Bausch Lomb Incorporated
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: This study will include subjects who meet all of the following: 1. Subjects must be 40 years of age or older on the date the Informed Consent Form (ICF) is signed. 2. Subjects must provide written informed consent on the IRB/EC-approved Informed Consent Form (ICF) and provide authorization as appropriate for local privacy protection regulations. 3. Subjects must be willing and able to comply with all treatment and follow-up study procedures. 4. Subjects undergoing optical coherence tomography (OCT) and fundus imaging must have adequate pupillary dilatation and clear media to perform imaging studies including fundus fluorescein angiography. 5. Subject must have a clinical indication for vitrectomy based on a diagnosis of one of the following conditions: vitreoretinal traction, asteroid hyalosis, macular pucker/epiretinal membrane, macular hole, or vitreous hemorrhage 6. Subject must have uncorrected visual acuity worse than 20/40 (Snellen) at Visit 1

Exclusion criteria

Exclusion criteria: The patients will be excluded from the study based on the following exclusion criteria: 1. Subjects who have participated in any drug or device clinical investigation within 30 days prior to entry into this study and/or will participate in another investigation during the period of study participation. 2. Subjects with retinal disorders in the study eye that may confound interpretation of or prevent obtaining fundus fluorescein angiography (FA) or OCT images, including retinal vascular occlusion, choroidal neovascularization, macular atrophy or scarring, ocular histoplasmosis, or pathologic myopia. 3. Subjects who have had prior vitrectomy surgery, cryopexy, or retinal buckle procedure. 4. Subjects with prior history of retinal tear, vitreoretinal tractional detachment, or ocular tumors in either eye. 5. Subjects with visual acuity of No Light Perception at Visit 1. 6. Female subjects of child-bearing potential who have a positive urine test for pregnancy at Visit 1. 7. Subjects who have experienced any significant trauma in the operative eye within the past month. 8. Subjects with any active ocular infection or history of any herpetic infection that has cleared less than one month prior to the pre-operative visit. 9. Subjects with history of complicated cataract surgery involving vitreous loss or a history of vitreoretinal surgery in the study eye. 10. Subjects with uncontrolled glaucoma or ocular hypertension (IOP > 24 mmHg) in the operative eye. 11. Subjects with dislocated lens or retained lens fragments. 12. Subjects with a known bleeding disorder or using drugs known to increase the likelihood of bleeding. 13. Subjects with uveitis refractory to treatment. 14. Subjects with significant anterior segment abnormality that would interfere with visualization of the vitreous or retina. 15. Subjects with a known allergy to sodium fluorescein dye. 16. Subjects with any medical condition (e.g., uncontrolled diabetes) that, based on the Investigatorâ??s medical judgment, poses a concern for the subjectsâ?? safety.

Design outcomes

Primary

MeasureTime frame
Evaluate the performance quality of a study device for pars plana vitrectomy surgery. Determine the range of time and device settings required to complete a vitrectomy Assess surgeon assessed device adequacy for removal of core / peripheral vitreous, vitreous hemorrhage and for induction of PVD in subjects requiring the use of a vitrector Verify no significantly different post surgical pathologic retinal changes due to study device Timepoint: NA

Secondary

MeasureTime frame
NATimepoint: NA

Countries

India

Contacts

Public ContactDr Sandeep Singh

Bousch & Lomb India

rakesh.prasad@bausch.com08800229917

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026